This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olsen, J. H. Articles by Olsen, J. Search for Related Content PubMed PubMed Citation Articles by Olsen, J. H. Articles by Olsen, J. Pubmed/NCBI databases Medline Plus Health Information Cancer

(Hypertension. 1997;29:1091-1094.)
© 1997 American Heart Association, Inc.

Articles

Cancer Risk in Users of Calcium Channel Blockers

Jørgen H. Olsen; Henrik Toft Sørensen; Søren Friis; Joseph K. McLaughlin; Flemming Hald Steffensen; Gunnar Lauge Nielsen; Morten Andersen; Joseph F. Fraumeni, Jr; ; Jørn Olsen

From the Danish Cancer Society, Division for Cancer Epidemiology, Copenhagen (J.H.O., S.F.); The Danish Epidemiology Science Centre, University of Aarhus (H.T.S., F.H.S., G.L.N., J.O.); Department of Internal Medicine V, Aarhus (Denmark) University (H.T.S.); International Epidemiology Institute, Rockville, Md (J.K.M.); Department of Internal Medicine M, Aalborg (Denmark) Hospital (G.L.N.); Department of Clinical Pharmacology, Odense (Denmark) University (M.A.); and National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, Md (J.F.F.).

Correspondence to Jørgen H. Olsen, Danish Cancer Society, Division for Cancer Epidemiology, Strandboulevarden 49, DK-2100 Copenhagen Ø, Denmark. E-mail jorgen{at}cancer.dk

Abstract Ca²⁺ channel blockers may cause cancer by inhibiting apoptosis or reducing intracellular Ca²⁺ in certain tissues. Recent findings suggest that drug users are at increased risk for cancer in general and for colon cancer in particular. We conducted a study in one Danish county of 17 911 patients who received at least one prescription of Ca²⁺ channel blockers between 1 January 1991 and 31 December 1993. The patients were identified from records in the National Health Insurance Program, which refunds part of the price of such drugs. Cancer occurrence and rate were determined by use of the files of the Danish Cancer Registry and compared with county-specific incidence rates for various categories of cancer. During the follow-up period of up to 3 years, 412 cancers were observed among users of Ca²⁺ channel blockers, compared with 414 expected, to yield an age- and sex-standardized incidence ratio (SIR) of 1.00 (95% confidence interval, 0.90 to 1.10). There was no indication of an excess risk in the subgroup of likely long-term users or users of specific drugs. The SIR of colon cancer, a site of a priori interest, was 0.8 (95% confidence interval, 0.5 to 1.1) on the basis of 34 cases. Although the results are reassuring, the lack of association could reflect the relatively short follow-up after registration in the prescription database. Continued monitoring of cancer risk is planned.

Key Words: calcium channel blockers • apoptosis • neoplasms • epidemiology • cohort studies

This article has been cited by other articles:

				J. D. Debes, R. O. Roberts, D. J. Jacobson, C. J. Girman, M. M. Lieber, D. J. Tindall, and S. J. Jacobsen Inverse Association between Prostate Cancer and the Use of Calcium Channel Blockers Cancer Epidemiol. Biomarkers Prev., February 1, 2004; 13(2): 255 - 259. [Abstract] [Full Text] [PDF]

				E Grossman, F.H Messerli, and U Goldbourt Antihypertensive therapy and the risk of malignancies Eur. Heart J., August 1, 2001; 22(15): 1343 - 1352. [Abstract] [PDF]

				M. Telez, B. Martinez, B. Criado, B. Ortega, O. Penagarikano, P. Flores, E. Ortiz-Lastra, and I. Arrieta Evaluation of the cytogenetic damage induced by the antihypertensive drug nimodipine in human lymphocytes Mutagenesis, July 1, 2001; 16(4): 345 - 351. [Abstract] [Full Text] [PDF]

				J. R. Kizer and S. E. Kimmel Epidemiologic Review of the Calcium Channel Blocker Drugs: An Up-to-date Perspective on the Proposed Hazards Arch Intern Med, May 14, 2001; 161(9): 1145 - 1158. [Abstract] [Full Text] [PDF]

				G. L. Nielsen, H. T. Sørensen, H. Larsen, and L. Pedersen Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study BMJ, February 3, 2001; 322(7281): 266 - 270. [Abstract] [Full Text]

				C. R. Meier, L. E. Derby, S. S. Jick, and H. Jick Angiotensin-Converting Enzyme Inhibitors, Calcium Channel Blockers, and Breast Cancer Arch Intern Med, February 14, 2000; 160(3): 349 - 353. [Abstract] [Full Text] [PDF]

				R. P. Mason Calcium channel blockers, apoptosis and cancer: is there a biologic relationship? J. Am. Coll. Cardiol., December 1, 1999; 34(7): 1857 - 1866. [Abstract] [Full Text] [PDF]

				D. R. Abernethy and J. B. Schwartz Calcium-Antagonist Drugs N. Engl. J. Med., November 4, 1999; 341(19): 1447 - 1457. [Full Text] [PDF]

				L. Rosenberg, R. S. Rao, J. R. Palmer, B. L. Strom, P. D. Stolley, A. G. Zauber, M. E. Warshauer, and S. Shapiro Calcium Channel Blockers and the Risk of Cancer JAMA, April 1, 1998; 279(13): 1000 - 1004. [Abstract] [Full Text] [PDF]